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Acute alcoholic hepatitis (AAH) is associated with a high 6-month mortality rate (70%) when patients are nonresponders or unable to receive medical therapy.
(1,2) Such a high rate makes it difficult to apply the 6-month alcohol abstinence rule. Moreover, this recommended duration of abstinence is not evidencebased. In extremely carefully selected patients with corticosteroid-resistant AAH, liver transplantation (LT) has been performed with promising results despite accelerated access to LT that deliberately violated the 6-month rule. (3) During that study, a 2-year survival rate of 78% was indeed reported.
This pilot study was started after the recommendations of the French consensus conference of Lyon in 2005. (4) On the basis of that experience, other programs in the United States have since started to offer LT in the context of severe AAH. Excellent 6-month survival (100%) and similar rates of alcohol relapse compared with patients with 6 months of abstinence have been published. (5) This suggests that significant changes in clinical practice may be ongoing worldwide.
The aim of the present study was to evaluate the impact of this recently proposed accelerated access to LT for AAH patients on the management of elective LT candidates for alcoholic cirrhosis in France, by means of an online survey.
Methods
A 20-item online survey (Supporting Material 1) was sent out to 163 practitioners (hepatologists, liver surgeons, anesthesiologists, and addictologists) working in the 18 French LT programs, in order to assess their clinical practices with respect to AAH and alcoholic cirrhosis. The results were analyzed at the levels of both physicians and centers. If different answers were given to the same question in a particular center, the most frequent response was taken into account.
Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics, version 23 (IBM, Armonk, NY). Descriptive analyses were carried out on all the data collected. Categorical variables were expressed as the numbers of Abbreviations: AAH, acute alcoholic hepatitis; ALD, alcoholic liver disease; LT, liver transplantation.
practitioners and percentages. Dichotomous variables were compared using the chi-square test or Fisher's exact test when appropriate. A P value of <0.05 was considered to indicate statistical significance, and all tests were 2-sided.
Results
The survey was completed by 62 (38%) practitioners, representing 17/18 of the centers to which it was circulated (94%). The response rate was significantly higher among hepatologists (52%) than surgeons (23%) or anesthesiologists (28%; P 5 0.002). The response rate from addictologists reached 50%. Overall, the average response rate was 4 practitioners per center (range, 0-8), with the survey being completed by at least 3 practitioners in 67% of centers (12/18).
The questions and related answers are described in Table 1 .
LT FOR AAH BEFORE AND AFTER 2011
The majority of centers (88%) declared they had changed their approach concerning AAH since 2011. Before 2011, 65% of centers had never performed LT in this indication, whereas 35% declared they had performed 1 (24%) or between 2 and 4 LTs (11%) for AAH each year, on a sporadic basis.
By 2011, all hepatologists and addictologists in 88% of centers (15/17) considered corticosteroid-resistant AAH to be a potential indication for LT in highly selected patients. In the 2 remaining centers, only 1 surgeon and 1 anesthesiologist disagreed, respectively.
After 2011, 71% of French centers began performing LT for AAH. However, half of the centers had enrolled their patients in the Quick-trans AAH prospective trial, and although 12% of centers replied that they had performed more than 5 LTs per year in this indication, 38% answered that they only occasionally transplanted AAH patients, and 13% never did so.
Overall therefore, 60% of centers reported on an increasing number of AAH patients being referred for potential LT.
Regarding the impact of AAH as a new indication for LT on the mortality rate among patients on the waiting list for other indications and graft shortage, 52% of practitioners replied that this could be expected to be deleterious. A difference was seen between hepatologists and anesthesiologists (44% and 33%, respectively) versus surgeons and addictologists (67% and 66%, respectively) regarding this response.
LT FOR ALCOHOLIC CIRRHOSIS EXCLUDING AAH
Changes were also observed regarding the number of LTs performed for alcoholic cirrhosis (excluding AAH): before 2011, 44%, 31%, and 25% of centers carried out 11-20, 21-40, and more than 40 LTs per year, respectively. These rates shifted to 25%, 44%, and 31%, respectively, after 2011, indicating that the proportion of patients transplanted for alcoholic liver disease (ALD) tended to rise in most centers, with only a minority of them performing fewer than 20 LTs for ALD since that cutoff point.
Although a majority of centers (76%) declared that they applied the 6-month abstinence rule when listing patients before 2011, 65% moved to a 3-month rule after 2011, with only 29% retaining the 6-month rule as a fundamental management principle. Before 2011, the 6-month abstinence rule to consider LT in patients with cirrhosis (with acute-on-chronic liver failure and without AAH) was 6 months in 29% of centers and between 3 and 6 months in 65%. After 2011, only 12% of centers continued to apply the 6-month abstinence rule: the minimum period of abstinence fell to 3-6 months or even to 1-2 months in 59% and 29% of centers, respectively. This means that 46% of centers reduced the duration of abstinence required before LT. The practitioners were also asked whether LT should be considered as a possible therapeutic option regardless of the abstinence period in patients with end-stage ALD: they replied "never," "yes always," and "only in selected patients" in 15%, 11%, and 74% of patients, respectively. Before 2011, addictologists were not involved in the management and evaluation of alcoholic patients in 24% of LT centers; this rose to 100% after 2011. Furthermore, before 2011, post-LT addiction outpatient clinic visits were never proposed in 12% of centers, but after that time 100% of centers offered this service.
Discussion
The results of the present survey show that the seminal publication by Mathurin et al. (3) on LT for AAH exerted a significant impact on French clinical practice and the behavior of practitioners with respect to LT not only for AAH but also for chronic ALD.
Following this publication, the majority (88%) of French LT centers started considering LT for AAH not only in the setting of multicenter prospective clinical trials but also outside such trials, indicating a remarkable adherence to the concept proposed by Mathurin et al. Recent publications from other groups show that this indication is growing beyond French borders. (5, 6) Moreover, this study seems to have triggered major changes to the management of LT for chronic non-AAH ALD, with a much more flexible approach regarding the 6-month rule for abstinence and a much more frequent involvement of addictologists in managing ALD candidates for LT. All these points were part of the recommendations of the consensus conference of Lyon in 2005.
This may be related to the practitioners' perception that strategies regarding abstinence should be kept as similar as possible for patients with ALD in order to preserve equality between patients, under the umbrella of a more strict and objective evaluation of alcoholrelated behavior by addictologists.
This trend now needs to be closely monitored, and the consequences of this more flexible approach regarding abstinence before LT should be carefully evaluated in terms of drinking behavior after LT, relapses after LT, and survival after LT in real life.
There are many issues other than abstinence in this indication that must be clarified in the next decade such as timing for listing, pre-LT checking, the place of living donor LT, impact on donation, and impact of infections and extrahepatic malignancies in short and longterm survival rates.
Caution is mandatory in programs to consider LT in alcoholic patients. Further clinical studies are necessary in order to redefine the place of LT in ALD.
